Alector Stock Price, News & Analysis

Alector, Inc. (Nasdaq: ALEC) has appointed Dr. Elizabeth (Betsy) A. Garofalo to its Board of Directors. With over 25 years in biopharmaceuticals, Dr. Garofalo brings extensive experience in global clinical development, especially in neurology. She has previously held significant roles at Novartis and Pfizer. Dr. Garofalo emphasized Alector's potential in neurology, particularly with its innovative immuno-neurology approach targeting degenerative diseases like Alzheimer’s and ALS. Her leadership is expected to enhance the company’s clinical programs as they advance into later-stage trials.

Alector (ALEC) has initiated a Phase 2 clinical trial for AL001 in patients with C9orf72-associated amyotrophic lateral sclerosis (ALS). This randomized, placebo-controlled study will involve approximately 45 participants who will receive AL001 or placebo intravenously every four weeks. The trial aims to evaluate safety, tolerability, and pharmacodynamics, focusing on progranulin levels. AL001 could potentially elevate brain progranulin levels, offering a neuroprotective effect against TDP-43 aggregation, which is linked to ALS pathology. This study represents a significant step towards developing targeted ALS treatments.

Alector, Inc. (Nasdaq: ALEC) announces organizational changes with Shehnaaz Suliman and Robert Paul stepping down as President and Chief Medical Officer, respectively. Sam Jackson appointed as interim Chief Medical Officer. Suliman and Paul will assist during the transition until year-end. Alector has six clinical studies ongoing for four candidates and plans to introduce new treatments in 2022. The CEO expresses gratitude for their contributions, stating the company is well-positioned for future growth in immuno-neurology.

Alector, a clinical-stage biotechnology company pioneering immuno-neurology, has announced participation in several upcoming virtual investor conferences. Key events include:

• Citi’s 16th Annual Biopharma Virtual Conference: Sept 8 at 11:35 a.m. ET and Sept 9 at 1:25 p.m. ET.
• Wells Fargo Virtual Healthcare Conference: Sept 10 at 2:00 p.m. ET.
• Morgan Stanley 19th Annual Global Healthcare Conference: Sept 13 at 11:45 a.m. ET.

Webcasts will be available on the Alector website, with replays for 30 days.

Alector (NASDAQ: ALEC) reported its Q2 2021 financial results, highlighting collaboration revenue of $6.6 million, up from $3.2 million year-over-year. The company continues to advance its AL001 program in frontotemporal dementia (FTD-GRN), presenting twelve-month data showing a 47% clinical progression slowdown. Alector and GSK established a global partnership, granting Alector $700 million upfront and up to $1.5 billion in potential milestones. As of June 30, 2021, cash and investments totaled $319.6 million, sufficient for operations into mid-2024.

Alector, Inc. (Nasdaq: ALEC) reported promising outcomes from its Phase 2 INFRONT-2 study of AL001, targeting frontotemporal dementia (FTD) due to progranulin gene mutations. At the Alzheimer’s Association International Conference, data showed that AL001 restored progranulin to normal levels and slowed clinical progression by 47% compared to a matched control group. Safety results indicated a favorable profile with mild adverse effects in a small patient cohort. Alector plans to proceed with a Phase 3 study, further assessing AL001's efficacy and safety in FTD patients.

Alector, Inc. (Nasdaq: ALEC) announced an oral presentation on July 29, 2021, regarding the Phase 2 study of AL001 for frontotemporal dementia with a progranulin mutation, at the 2021 Alzheimer’s Association International Conference. The six- and twelve-month data from the open-label INFRONT-2 study will be discussed by Dr. Robert Paul, CMO. Additionally, two posters will present the AL002 Alzheimer’s disease program, including Phase 1 study results and INVOKE-2 trial design. The conference call will be held at 1:00 p.m. ET to review findings.

Alector and GSK have formed a strategic collaboration to co-develop monoclonal antibodies AL001 and AL101 aimed at treating multiple neurodegenerative diseases. This partnership includes a $700 million upfront payment and up to $1.5 billion in potential milestones. Alector will lead clinical development up to Phase 2, while both companies will share commercialization responsibilities in the U.S., with GSK handling international rights. The collaboration could significantly expand treatment options for conditions like frontotemporal dementia, ALS, Parkinson's, and Alzheimer’s.

Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced that Dr. Shehnaaz Suliman will participate in two upcoming investor conferences. The events include the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. ET, and the BofA Securities 2021 Napa Biopharma Virtual Conference on June 14, 2021, at 5:30 p.m. ET. Live webcasts will be accessible on Alector's website, with replays available for 30 days post-event. Alector is focused on developing therapies for neurodegenerative diseases by targeting immune dysfunction.